NWBO Northwest Biotherapeutics, Inc.

-

Northwest Biotherapeutics Reported Earnings

Friday, November 13, 2026 · 12:00 AM ET

Northwest Biotherapeutics (NWBO) reported a loss of $0.02 per share on revenue of $0.88 million for the . . Revenue grew 341.50% on a year-over-year basis.

Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($0.02)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth99.9 %
Reported Revenue
$0.88M
Revenue Estimate
—
Revenue Surprise
Revenue Growth341.5 %